Eliem Therapeutics
Manufacturing · Delaware, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2801 Centerville Rd # 1, Wilmington, Del...Phone Number
(877) 354-3689Website
www.eliemtx.comRevenue
$19.8 MillionStock Symbol
ELYMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Eliem Therapeutics
Eliem Therapeutics is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis.Explore more
Eliem Therapeutics Org Chart
SL
Senior Director, Clinical Pharmacology
JK
Director
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eliem Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Eliem Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Eliem Therapeutics has new funding data
Eliem Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Eliem Therapeutics
Website visits: Recent activity has been detected on your website
Check out if Eliem Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Eliem Therapeutics had a recent Job posting/layoffs
Check if Eliem Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Eliem Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Eliem Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Eliem Therapeutics
Compare insights from companies similar to Eliem Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Eliem Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eliem Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eliem Therapeutics.
Eliem Therapeutics financials insights
Gather financial insights about Eliem Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$10M
2021
Multiple Rounds
$220M
Eliem Therapeutics Tech Stack
A closer look at the technologies used by Eliem Therapeutics
Most Recent Scoops
Project
Eliem Therapeutics is developing treatments for immune-mediated diseases affecting one in seven Americans, focusing on clinically validated biology with potential for multiple indications. The company's approach targets a growing global market opportunity with differentiated treatment potential.
Search, Medical Research, Pharmaceuticals, Clinical Operations, Operations
Project
Eliem Therapeutics is developing two assets: Bhuto protect, an anti-CD19 B cell depleting monoclonal antibody, and It climb 116, an anti-April monoclonal antibody for IgA Nephropathy.
Search, Medical Research, Pharmaceuticals
Project
believes CD19 is the best target for B cell mediated diseases due to its expression pattern, which translates into meaningful clinical impact by depleting the right subset of B cells.
Search, Medical Research, Pharmaceuticals
Project
Eliem Therapeutics is categorizing B cell mediated disease opportunities into three sets: IgG4 mediated diseases (lead: primary membranous nephropathy), single organ rare autoimmune diseases (lead: immune thrombocytopenia), and complex systemic diseases (e.g., SLE).
Search, Medical Research, Pharmaceuticals
Project
Search, Medical Research, Pharmaceuticals, Clinical Operations, Operations
Eliem Therapeutics News & Media
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
Name change to "Climb Bio" marks the Company’s transition and focus on developing treatments for immune-mediated diseasesEliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.Eliem Therapeutics Announces Additions to its Leadership Team
Brett Kaplan, M.D. appointed Chief Operating OfficerEliem Therapeutics Reports Second Quarter Financial Results
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eliem Therapeutics
Sign Up For FreeTo access detailed company insights
Eliem Therapeutics is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restori... Read More
